This association of high levels of ECT2-Ex5 inclusion with bad prognosis specifically in case of chemotherapeutic treatment, was even more pronounced in the HR+ERBB2– subtype of breast cancer (Figure 7C). This evidence concerns the gene ECT2 and breast carcinoma.